Show simple item record

dc.contributor.author Szabó, Dolóresz
dc.contributor.author Hosszú E,
dc.contributor.author Arató, András
dc.contributor.author Müller, Katalin Eszter
dc.contributor.author Béres, Nóra
dc.contributor.author Lakatos, Péter László
dc.contributor.author Papp, Mária
dc.contributor.author Dezsőfi, Antal
dc.contributor.author Szabó, Attila
dc.contributor.author Szűcs D
dc.contributor.author Veres, Gábor
dc.date.accessioned 2015-11-05T14:53:36Z
dc.date.available 2015-11-05T14:53:36Z
dc.date.issued 2015
dc.identifier 84937525626
dc.identifier.citation pagination=652-657; journalVolume=47; journalIssueNumber=8; journalTitle=DIGESTIVE AND LIVER DISEASE;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2148
dc.identifier.uri doi:10.1016/j.dld.2015.05.006
dc.description.abstract BACKGROUND: Paediatric Crohn's disease patients suffer from several complications, including low bone mineral density and inadequate serum levels of 25-hydroxy vitamin D. AIMS: The aim of this prospective study was to address the effect of infliximab therapy on bone metabolism, bone mineral density and vitamin D homeostasis. The seasonal variability of serum vitamin D levels in relation to infliximab treatment was also analysed. METHODS: Serum osteocalcin and beta-crosslaps (markers of bone metabolism), seasonal variability of vitamin D, and bone mineral density were assessed and followed throughout the yearlong treatment regimen of infliximab in 50 consecutive paediatric patients with moderate to severe Crohn's disease. RESULTS: Bone forming osteocalcin levels were significantly (p<0.001) increased during infliximab therapy. In contrast, no significant changes in beta-crosslaps and vitamin D levels were observed. Vitamin D levels were significantly different when the summer and winter periods were compared at week 0 (p=0.039); however, this difference was not detected after one year of infliximab therapy. Despite the beneficial clinical effect of infliximab, there was no significant change in bone mineral density Z-scores after one year of treatment. CONCLUSION: Infliximab may beneficially affect bone homeostasis. Moreover, seasonal variability in vitamin D levels observed prior to initiation of infliximab treatment was diminished after one year of treatment.
dc.relation.ispartof urn:issn:1590-8658
dc.title Seasonal variability of vitamin-D and bone metabolism in infliximab-treated pediatric patients with Crohn's disease
dc.type Journal Article
dc.date.updated 2015-08-31T09:51:24Z
dc.language.rfc3066 en
dc.identifier.mtmt 2890638
dc.identifier.pubmed 26074152
dc.contributor.department SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika
dc.contributor.department SE/AOK/K/ISZGYK/MTA-SE Gyermekgyógyászati és Nephrológiai Kutatócsoport
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.department SE/AOK/K/I. Sz. Belgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account